Acceleron Pharma (XLRN) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a report published on Monday morning. HC Wainwright currently has a $62.00 price objective on the biopharmaceutical company’s stock.

XLRN has been the topic of several other reports. Cann restated a hold rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Oppenheimer restated a hold rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Barclays raised their price objective on shares of Acceleron Pharma from $42.00 to $50.00 and gave the company an overweight rating in a research report on Wednesday, September 20th. UBS restated a buy rating and set a $50.00 price objective (up from $36.00) on shares of Acceleron Pharma in a research report on Tuesday, September 12th. Finally, ValuEngine upgraded shares of Acceleron Pharma from a sell rating to a hold rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Acceleron Pharma currently has a consensus rating of Buy and an average target price of $44.56.

Acceleron Pharma (NASDAQ XLRN) opened at $35.92 on Monday. Acceleron Pharma has a one year low of $23.07 and a one year high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.55) EPS. sell-side analysts predict that Acceleron Pharma will post -2.65 earnings per share for the current year.

In related news, major shareholder Corp /De/ Celgene purchased 745,592 shares of Acceleron Pharma stock in a transaction on Monday, September 25th. The shares were bought at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the acquisition, the insider now owns 6,118,479 shares in the company, valued at approximately $226,383,723. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP John D. Quisel sold 5,113 shares of Acceleron Pharma stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the completion of the sale, the senior vice president now owns 57,918 shares in the company, valued at $2,225,209.56. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of XLRN. Quantbot Technologies LP increased its holdings in shares of Acceleron Pharma by 416.3% in the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,352 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Acceleron Pharma by 969.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 3,288 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Acceleron Pharma in the 3rd quarter worth about $225,000. PNC Financial Services Group Inc. increased its holdings in shares of Acceleron Pharma by 57.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 3,100 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Acceleron Pharma in the 3rd quarter worth about $266,000. Hedge funds and other institutional investors own 85.84% of the company’s stock.

WARNING: “Acceleron Pharma (XLRN) Given “Buy” Rating at HC Wainwright” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/12/12/acceleron-pharma-xlrn-given-buy-rating-at-hc-wainwright.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply